2017

Take a break and read all about it

Phase III APHINITY study shows Roche’s Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy

Monet St Juste 23 September 2022

APHINITY study shows Roche’s Perjeta®-based regimen reduced the risk of invasive cancer returning compared to Herceptin® and chemotherapy in HER2-positive early breast cancer

Monet St Juste 23 September 2022

SOLE (Study of Letrozole Extension):A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer

Monet St Juste 23 September 2022

Primary results of LORELEI study presentedat ESMO 2017 Congress

Monet St Juste 23 September 2022

PANACEA study suggests immunotherapy may help to overcome trastuzumab-resistant breast cancer

Monet St Juste 23 September 2022

Ovarian Suppression Reduces Recurrence for Young Breast Cancer Patients

Monet St Juste 23 September 2022

Do You Want To Boost Your Business?

drop us a line and keep in touch

Breast international group (BIG) – aisbl

Rue de bretagne 20,
1200 Brussels, Belgium
VAT BE 0468 176 240
IBAN BE08 0689 0916 0213

Navigation

The Breast International Group is proud to adhere
to the Code of Ethics of the VEF-AERF

© 2022 All rights reserved

Breast international group (BIG) - aisbl